JSPRW - Jasper Therapeutics Inc - Warrants (24/09/2026)
Previous close
0.217
0 0%
Share volume: 4,847
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.22
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.05%
1 Month
-1.41%
3 Months
8.45%
6 Months
-5.65%
1 Year
269.51%
2 Year
147.89%
Key data
Stock price
$0.22
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.04 - $0.38
52 WEEK CHANGE
$2.14
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: jaspertherapeutics.com
Employees: 40
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: jaspertherapeutics.com
Employees: 40
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
jasper therapeutics is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. jasper’s lead compound, jsp191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
Recent news